Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Mark Jacob Siedner, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Mark Siedner and Jessica Haberer.
Mark Siedner
Connection Strength
6.582
Jessica Haberer
  1. Optimizing network connectivity for mobile health technologies in sub-Saharan Africa. PLoS One. 2012; 7(9):e45643.
    View in: PubMed
    Score: 0.500
  2. High residual inflammation despite HIV viral suppression: Lessons learned from real-time adherence monitoring among people with HIV in Africa. HIV Med. 2022 05; 23(5):465-473.
    View in: PubMed
    Score: 0.234
  3. Treated HIV Infection and Progression of Carotid Atherosclerosis in Rural Uganda: A Prospective Observational Cohort Study. J Am Heart Assoc. 2021 06 15; 10(12):e019994.
    View in: PubMed
    Score: 0.228
  4. Antiretroviral Therapy Adherence Interruptions Are Associated With Systemic Inflammation Among Ugandans Who Achieved Viral Suppression. J Acquir Immune Defic Syndr. 2019 12 01; 82(4):386-391.
    View in: PubMed
    Score: 0.205
  5. Inflammatory biomarkers prior to antiretroviral therapy as prognostic markers of 12-month mortality in South Africa and Uganda. AIDS. 2019 11 01; 33(13):2043-2048.
    View in: PubMed
    Score: 0.204
  6. Timing of Antiretroviral Therapy and Systemic Inflammation in Sub-Saharan Africa: Results From the META Longitudinal Cohort Study. J Infect Dis. 2019 08 30; 220(7):1172-1177.
    View in: PubMed
    Score: 0.202
  7. ART adherence and viral suppression are high among most non-pregnant individuals with early-stage, asymptomatic HIV infection: an observational study from Uganda and South Africa. J Int AIDS Soc. 2019 02; 22(2):e25232.
    View in: PubMed
    Score: 0.194
  8. Advancing equitable global health research partnerships in Africa. BMJ Glob Health. 2018; 3(4):e000868.
    View in: PubMed
    Score: 0.188
  9. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies. AIDS Res Hum Retroviruses. 2018 11; 34(11):982-992.
    View in: PubMed
    Score: 0.188
  10. Distribution and Performance of Cardiovascular Risk Scores in a Mixed Population of HIV-Infected and Community-Based HIV-Uninfected Individuals in Uganda. J Acquir Immune Defic Syndr. 2018 08 01; 78(4):458-464.
    View in: PubMed
    Score: 0.187
  11. Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013. AIDS Patient Care STDS. 2018 07; 32(7):257-264.
    View in: PubMed
    Score: 0.186
  12. Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study. Ann Intern Med. 2018 08 07; 169(3):146-155.
    View in: PubMed
    Score: 0.186
  13. Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression. J Acquir Immune Defic Syndr. 2018 04 15; 77(5):507-513.
    View in: PubMed
    Score: 0.183
  14. The Technology Acceptance Model for Resource-Limited Settings (TAM-RLS): A Novel Framework for Mobile Health Interventions Targeted to Low-Literacy End-Users in Resource-Limited Settings. AIDS Behav. 2017 Nov; 21(11):3129-3140.
    View in: PubMed
    Score: 0.178
  15. Brief Report: Appraising Viral Load Thresholds and Adherence Support Recommendations in the World Health Organization Guidelines for Detection and Management of Virologic Failure. J Acquir Immune Defic Syndr. 2017 10 01; 76(2):183-187.
    View in: PubMed
    Score: 0.177
  16. Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa? J Acquir Immune Defic Syndr. 2017 10 01; 76(2):188-192.
    View in: PubMed
    Score: 0.177
  17. Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda. AIDS Behav. 2017 Jun; 21(6):1735-1740.
    View in: PubMed
    Score: 0.173
  18. Cooking fuel and respiratory symptoms among people living with HIV in rural Uganda. ERJ Open Res. 2017 Apr; 3(2).
    View in: PubMed
    Score: 0.172
  19. Impact of a clinical program using weekly Short Message Service (SMS) on antiretroviral therapy adherence support in South Africa: a retrospective cohort study. BMC Med Inform Decis Mak. 2017 Feb 20; 17(1):18.
    View in: PubMed
    Score: 0.169
  20. D-Dimer Levels and Traditional Risk Factors Are Associated With Incident Hypertension Among HIV-Infected Individuals Initiating Antiretroviral Therapy in Uganda. J Acquir Immune Defic Syndr. 2016 Dec 01; 73(4):396-402.
    View in: PubMed
    Score: 0.167
  21. The Acceptability and Perceived Usefulness of a Weekly Clinical SMS Program to Promote HIV Antiretroviral Medication Adherence in KwaZulu-Natal, South Africa. AIDS Behav. 2016 11; 20(11):2629-2638.
    View in: PubMed
    Score: 0.166
  22. HIV infection and arterial stiffness among older-adults taking antiretroviral therapy in rural Uganda. AIDS. 2016 Feb 20; 30(4):667-70.
    View in: PubMed
    Score: 0.158
  23. Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda. J Acquir Immune Defic Syndr. 2015 Dec 01; 70(4):386-92.
    View in: PubMed
    Score: 0.156
  24. Persistent Immune Activation and Carotid Atherosclerosis in HIV-Infected Ugandans Receiving Antiretroviral Therapy. J Infect Dis. 2016 Feb 01; 213(3):370-8.
    View in: PubMed
    Score: 0.153
  25. A combination SMS and transportation reimbursement intervention to improve HIV care following abnormal CD4 test results in rural Uganda: a prospective observational cohort study. BMC Med. 2015 Jul 06; 13:160.
    View in: PubMed
    Score: 0.151
  26. Know your audience: predictors of success for a patient-centered texting app to augment linkage to HIV care in rural Uganda. J Med Internet Res. 2015 Mar 24; 17(3):e78.
    View in: PubMed
    Score: 0.148
  27. Empiric deworming and CD4 count recovery in HIV-infected Ugandans initiating antiretroviral therapy. PLoS Negl Trop Dis. 2014 Aug; 8(8):e3036.
    View in: PubMed
    Score: 0.142
  28. Treatment as long-term prevention: sustained reduction in HIV sexual transmission risk with use of antiretroviral therapy in rural Uganda. AIDS. 2014 Jan 14; 28(2):267-71.
    View in: PubMed
    Score: 0.137
  29. Realtime adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS. 2013 Aug 24; 27(13):2166-8.
    View in: PubMed
    Score: 0.133
  30. Disinhibition in risky sexual behavior in men, but not women, during four years of antiretroviral therapy in rural, southwestern Uganda. PLoS One. 2013; 8(7):e69634.
    View in: PubMed
    Score: 0.132
  31. GPS-measured distance to clinic, but not self-reported transportation factors, are associated with missed HIV clinic visits in rural Uganda. AIDS. 2013 Jun 01; 27(9):1503-8.
    View in: PubMed
    Score: 0.131
  32. Sexual relationship power and malnutrition among HIV-positive women in rural Uganda. AIDS Behav. 2012 Aug; 16(6):1542-8.
    View in: PubMed
    Score: 0.124
  33. Rethinking the "pre" in pre-therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugandans initiating ARVs. PLoS One. 2012; 7(6):e39894.
    View in: PubMed
    Score: 0.123
  34. High acceptability for cell phone text messages to improve communication of laboratory results with HIV-infected patients in rural Uganda: a cross-sectional survey study. BMC Med Inform Decis Mak. 2012 Jun 21; 12:56.
    View in: PubMed
    Score: 0.123
  35. Perceptions About Local ART Adherence Norms and Personal Adherence Behavior Among Adults Living with HIV in Rural Uganda. AIDS Behav. 2022 Jun; 26(6):1892-1904.
    View in: PubMed
    Score: 0.060
  36. Internalized stigma, depressive symptoms, and the modifying role of antiretroviral therapy: A cohort study in rural Uganda. SSM Ment Health. 2021 Dec; 1.
    View in: PubMed
    Score: 0.059
  37. Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda. AIDS. 2021 06 01; 35(7):1083-1089.
    View in: PubMed
    Score: 0.057
  38. Association between obesity and combination antiretroviral therapy (cART) adherence among persons with early-stage HIV infection initiating cART. Int J Obes (Lond). 2021 08; 45(8):1855-1859.
    View in: PubMed
    Score: 0.057
  39. Who is telling the story? A systematic review of authorship for infectious disease research conducted in Africa, 1980-2016. BMJ Glob Health. 2019; 4(5):e001855.
    View in: PubMed
    Score: 0.051
  40. Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches. AIDS. 2017 11 13; 31(17):2345-2354.
    View in: PubMed
    Score: 0.045
  41. HIV-Infected Ugandan Women on Antiretroviral Therapy Maintain HIV-1 RNA Suppression Across Periconception, Pregnancy, and Postpartum Periods. J Acquir Immune Defic Syndr. 2016 Apr 01; 71(4):399-406.
    View in: PubMed
    Score: 0.040
  42. Persistent HIV-related stigma in rural Uganda during a period of increasing HIV incidence despite treatment expansion. AIDS. 2015 Jan 02; 29(1):83-90.
    View in: PubMed
    Score: 0.037
  43. Persistent HIV-related Stigma in Rural Uganda during a Period of Increasing HIV Incidence. AIDS Res Hum Retroviruses. 2014 Oct; 30 Suppl 1:A259.
    View in: PubMed
    Score: 0.036
  44. CD4+ cell count at antiretroviral therapy initiation and economic restoration in rural Uganda. AIDS. 2014 May 15; 28(8):1221-6.
    View in: PubMed
    Score: 0.035
  45. Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural Uganda. J Acquir Immune Defic Syndr. 2013 Mar 01; 62(3):317-21.
    View in: PubMed
    Score: 0.032
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.